Suspended

ProbiEntProbiotics for Reduction of Colonisation With Clostridium Difficile in Antibiotic Treated Intensive Care Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

L. plantarum 299 and L. plantarum 299v (+maltodextrin)

+ Maltodextrin

Dietary SupplementOther
Who is being recruted

Over 18 Years
+9 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Prevention Study

Placebo-Controlled
Interventional
Study Start: June 2012
See protocol details

Summary

Principal SponsorRegion Skane
Last updated: October 5, 2017
Sourced from a government-validated database.Claim as a partner

Study start date: June 1, 2012

Actual date on which the first participant was enrolled.

Infections with Clostridium difficile is considered to be the most frequent health care associated bacterial infection. Almost all cases are connected to the use of antibiotics. The spectra of symptoms of infection reaches from loose stools to sepsis and death. It is estimated that about 5% of the population are carriers without symptoms. Elderly people are more likely to be diagnosed with C. difficile infections and as about 50 % of ICU admissions (at least in Sweden) are patients aged 64 years or older C. difficile is also an ICU issue. Probiotic bacteria given to antibiotic treated patients results in fever cases of infection with C. difficile as we and others have shown in some small studies. Due to a low statistical power in our former study this multicentre study is calculated to be large enough to fulfil statistical requirements. Adult patients with an expected length of stay in intensive care for three days or more can be included. Primary objective is to find emerging cases of colonisation with C. difficile and consequent symptoms of infection such as diarrhoea. Cultures and toxin analyses will be taken at inclusion and every second day till day 13 and then every third or fourth day depending on length of ICU stay. Positive cases will be given antibiotics according to normal routines. No other cultures are collected per protocol but all cultures will be recorded and results will be analysed in order to find any connection between treatment and reduction of secondary infections. In our earlier small study we found an improved and normalised gut barrier function for those patients that were given probiotic bacteria compared to a worsened, scattered pattern for the placebo group. This is probably why we found that inflammatory parameters improved for the probiotics group while those parameters remained elevated for the control patients. The same goes for creatinine, urea and lactate. This is why we will record those parameters together with blood gas analyses in this expanded study. Antibiotics and medication with corticosteroids, proton pump inhibitors or other acid reducing preparations, All nutritive prescriptions (enteral formulas and IV solutions as well as medical preparations containing glucose or fat) will be recorded and compared to actually given nutrients. Bowel movements frequency and consistency will be recorded and compared between groups.

Principal SponsorRegion Skane
Last updated: October 5, 2017
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

25 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Prevention Study

Prevention studies aim to stop a disease from developing. They often involve people at risk and test things like vaccines, lifestyle changes, or preventive medications.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

3 inclusion criteria required to participate
Antibiotics on-going or planned

Anticipated need for intensive care 3 days or longer

Patients condition allowing enteral nutrition to be started within 24 h from ICU admission

6 exclusion criteria prevent from participating
Enteral nutrition contra indicated

ICU admission earlier during this period of illness Patient being moribund

Known immune deficiencies

Known positive test for Clostridium difficile within the last week

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water through a nasogastric tube. Patients randomized 1:1 between groups

Group II

Placebo
Patients will be given only the dissolved maltodextrin in water through the nasogastric tube. Patients randomized 1:1 between groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 4 locations

Intensive Care Unit, Helsingborg Hospital

Helsingborg, SwedenOpen Intensive Care Unit, Helsingborg Hospital in Google Maps

Intensive Care Unit, Kristianstad Central hospital

Kristianstad, Sweden

Lund University Hospital

Lund, Sweden

Dept of Anesthesia & Intensive Care, University Hospital of Norrland

Umeå, Sweden
Suspended4 Study Centers